Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 321-327

  Rusovici, Raluca ^a   Patel, Chirag J ^a   Chalam, Kakarla V ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; PROPIDIUM IODIDE; VASCULOTROPIN 165;

ANIMAL CELL; ARTICLE; BRIGHT FIELD MICROSCOPY; CELL ASSAY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CHOROID; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOCHEMISTRY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HAPLORHINI; INHIBITION KINETICS; NONHUMAN;

EID: 84874893670     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S41556     Document Type: Article

References (21)

1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293.
2. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no 1. Control Clin Trials. 1999;20:573-600.
3. Citirik M, Kabatas EU, Batman C, Akin KO, Kabatas N. Vitreous vas-cular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy. Ophthalmic Res. 2012;47:7-12.
4. Brar VS, Sharma RK, Murthy RK, Chalam KV. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells. J Ocul Pharmacol Ther. 2009;25:507-511.
5. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no 8. Arch Ophthalmol. 2001;19: 1417-1436.
6. Bressler NM, Bressler SB. Preventative ophthalmology: age-related macular degeneration. Ophthalmology.1995;102:1206-1211.
7. Shimomura Y, Hirata A, Ishikawa S, Okinami S. Changes in choriocap-illaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol. 2009;247:1089-1094.
8. McLaughlin AP, De Vries GW. Role of PLCgamma and Ca(2+) in VEGF-and FGF-induced choroidal endothelial cell proliferation. Am J Physiol Cell Physiol. 2001;281:1448-1456.
9. Zubilewicz A, Hecquet C, Jeanny JC, Soubrane G, Courtois Y, Mascarelli F. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a compara-tive study with VEGF. Oncogene. 2001;20:1403-1413.
10. Brown DM, Kaiser PK, Michels M, et al. ANCHOR study group ranibi-zumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
11. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibi-zumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
13. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. 2-year results of the MARINA study. N Engl J Med. 2006;355:1419-1431.
14. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovas-cular age-related macular degeneration. N Engl J Med. 2011;364: 1897-1908.
15. Fasanaro P, Capogrossi MC, Martelli F. Regulation of the endothelial cell cycle by the ubiquitin-proteasome system. Cardiovasc Res. 2010;85: 272-280.
16. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007;26:281-290.
17. Amrite AC, Kompella UB. Celecoxib inhibits proliferation of retinal pig-ment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther. 2008;324: 749-758.
18. Geisen P, McColm JR, Hartnett ME. Choroidal endothelial cells trans-migrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. Exp Eye Res. 2006;82:608-619.
19. Takeda A, Hata Y, Shiose S, et al. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch Clin Exp Ophthalmol. 2003;241:765-772.
20. Kuo CN, Chen CY, Lai CH, et al. Cell cycle regulation by bevacizumab in ARPE-19 human retinal pigment epithelial cells. Mol Med Report. 2012;6:701-704.
21. Kim JH, Lee BJ, Kim JH, Yu YS, Kim MY, Kim KW. Rosmarinic acid suppresses retinal neovascularization via cell cycle arrest with increase of p21 (WAF1) expression. Eur J Pharmacol. 2009;615:150-154.